Prestige Consumer Healthcare Inc. (PBH) P/E Ratio History
Fairly ValuedTrading at 13.2x, near 5Y avg of 15.5x · 15th percentile · In line with own history · Data 2006–2027
Loading P/E history...
P/E Ratio Analysis
As of November 7, 2026, Prestige Consumer Healthcare Inc. (PBH) trades at a price-to-earnings ratio of 13.2x, with a stock price of $42.98 and trailing twelve-month earnings per share of $3.26.
The current P/E is 15% below its 5-year average of 15.5x. Over the past five years, PBH's P/E has ranged from a low of 10.6x to a high of 20.0x, placing the current valuation at the 15th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, PBH trades at a 46% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
The PEG ratio of 3.50 (P/E divided by -9% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, PBH trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PBH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PBH Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PBH P/E vs Peers
Consumer and Animal Health peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 25.1 | 1.94Best | -6% | |
| $26B | 33.7 | - | +27% | |
| $2B | 20.2 | - | +538%Best | |
| $37B | 22.0 | - | +41% | |
| $41B | 19.0Lowest | 2.25 | +13% | |
| $1B | 75.2 | - | +104% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PBH Historical P/E Data (2006–2027)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2027 Q2 | Sep 30 2026 | $45.87 | $3.24 | 14.2x | -25% |
| FY2027 Q1 | - | $47.27 | $3.57 | 13.2x | -30% |
| FY2026 Q4 | - | $59.27 | $3.91 | 15.2x | -20% |
| FY2026 Q3 | Dec 31 2025 | $61.69 | $3.78 | 16.3x | -14% |
| FY2026 Q2 | - | $62.40 | $4.03 | 15.5x | -18% |
| FY2026 Q1 | Jun 30 2025 | $79.85 | $4.26 | 18.7x | -1% |
| FY2025 Q4 | Mar 31 2025 | $85.97 | $4.29 | 20.0x | +6% |
| FY2025 Q3 | - | $78.09 | $4.27 | 18.3x | -4% |
| FY2025 Q2 | Sep 30 2024 | $72.10 | $4.11 | 17.5x | -7% |
| FY2025 Q1 | Jun 30 2024 | $68.85 | $4.09 | 16.8x | -11% |
| FY2024 Q4 | Mar 31 2024 | $72.56 | $4.17 | 17.4x | -8% |
| FY2023 Q3 | Dec 31 2022 | $62.60 | $4.17 | 15.0x | -21% |
| FY2023 Q2 | Sep 30 2022 | $49.83 | $4.12 | 12.1x | -36% |
| FY2023 Q1 | - | $58.80 | $3.99 | 14.7x | -22% |
| FY2022 Q4 | - | $52.94 | $4.04 | 13.1x | -31% |
| FY2022 Q3 | Dec 31 2021 | $60.65 | $3.72 | 16.3x | -14% |
| FY2022 Q2 | - | $56.13 | $3.54 | 15.9x | -16% |
| FY2022 Q1 | Jun 30 2021 | $52.10 | $3.53 | 14.8x | -22% |
| FY2021 Q4 | Mar 31 2021 | $44.08 | $3.25 | 13.6x | -28% |
| FY2021 Q3 | - | $34.87 | $3.28 | 10.6x | -44% |
| FY2021 Q2 | Sep 30 2020 | $36.42 | $3.22 | 11.3x | -40% |
| FY2021 Q1 | - | $37.56 | $2.99 | 12.6x | -34% |
| FY2020 Q4 | - | $36.68 | $2.78 | 13.2x | -30% |
| FY2019 Q3 | Dec 31 2018 | $30.88 | $1.22 | 25.3x | +33% |
| FY2019 Q2 | Sep 30 2018 | $37.89 | $6.37 | 5.9x | -69% |
| FY2019 Q1 | Jun 30 2018 | $38.38 | $6.35 | 6.0x | -68% |
| FY2018 Q4 | Mar 31 2018 | $33.72 | $6.33 | 5.3x | -72% |
| FY2018 Q3 | Dec 31 2017 | $44.41 | $7.29 | 6.1x | -68% |
| FY2018 Q2 | Sep 30 2017 | $50.09 | $2.00 | 25.0x | +32% |
| FY2018 Q1 | Jun 30 2017 | $52.81 | $2.03 | 26.0x | +37% |
| FY2017 Q4 | Mar 31 2017 | $55.56 | $1.30 | 42.7x | +125% |
| FY2017 Q3 | Dec 31 2016 | $52.10 | $1.35 | 38.6x | +104% |
| FY2017 Q2 | Sep 30 2016 | $48.27 | $1.29 | 37.4x | +97% |
| FY2017 Q1 | - | $55.40 | $1.29 | 42.9x | +126% |
| FY2016 Q4 | - | $53.39 | $1.88 | 28.4x | +50% |
| FY2016 Q3 | - | $51.48 | $2.07 | 24.9x | +31% |
| FY2016 Q2 | Sep 30 2015 | $45.16 | $1.94 | 23.3x | +23% |
| FY2016 Q1 | - | $46.24 | $1.65 | 28.0x | +48% |
| FY2015 Q4 | - | $42.89 | $1.48 | 29.0x | +53% |
| FY2015 Q3 | Dec 31 2014 | $34.72 | $1.33 | 26.1x | +38% |
| FY2015 Q2 | - | $32.37 | $0.99 | 32.7x | +72% |
| FY2015 Q1 | Jun 30 2014 | $33.89 | $1.31 | 25.9x | +36% |
| FY2014 Q4 | Mar 31 2014 | $27.25 | $1.39 | 19.6x | +3% |
| FY2014 Q3 | - | $35.80 | $1.46 | 24.5x | +29% |
| FY2014 Q2 | Sep 30 2013 | $30.12 | $1.64 | 18.4x | -3% |
| FY2014 Q1 | Jun 30 2013 | $29.14 | $1.39 | 21.0x | +11% |
| FY2013 Q4 | Mar 31 2013 | $25.69 | $1.28 | 20.1x | +6% |
| FY2013 Q3 | Dec 31 2012 | $20.03 | $0.91 | 22.0x | +16% |
| FY2013 Q2 | Sep 30 2012 | $16.96 | $0.86 | 19.7x | +4% |
| FY2013 Q1 | Jun 30 2012 | $15.81 | $0.74 | 21.4x | +13% |
| FY2012 Q4 | Mar 31 2012 | $17.48 | $0.74 | 23.6x | +25% |
| FY2012 Q3 | Dec 31 2011 | $11.27 | $0.87 | 13.0x | -32% |
| FY2012 Q2 | Sep 30 2011 | $9.05 | $0.72 | 12.6x | -34% |
| FY2012 Q1 | - | $12.84 | $0.68 | 18.9x | -0% |
| FY2011 Q4 | - | $11.50 | $0.58 | 19.8x | +5% |
| FY2011 Q3 | Dec 31 2010 | $11.95 | $0.52 | 23.2x | +22% |
| FY2011 Q2 | - | $9.89 | $0.69 | 14.4x | -24% |
| FY2011 Q1 | Jun 30 2010 | $7.08 | $0.67 | 10.6x | -44% |
| FY2010 Q4 | Mar 31 2010 | $9.00 | $0.65 | 13.9x | -26% |
| FY2009 Q3 | Dec 31 2008 | $10.55 | $0.70 | 15.1x | -21% |
| FY2009 Q2 | - | $8.88 | $0.71 | 12.5x | -34% |
| FY2009 Q1 | Jun 30 2008 | $10.66 | $0.68 | 15.7x | -17% |
| FY2008 Q4 | Mar 31 2008 | $8.18 | $0.69 | 11.9x | -37% |
| FY2008 Q3 | Dec 31 2007 | $7.48 | $0.65 | 11.5x | -39% |
| FY2008 Q2 | Sep 30 2007 | $10.98 | $0.69 | 15.9x | -16% |
| FY2008 Q1 | Jun 30 2007 | $12.98 | $0.73 | 17.8x | -6% |
| FY2007 Q4 | Mar 31 2007 | $11.85 | $0.73 | 16.2x | -14% |
| FY2007 Q3 | Dec 31 2006 | $13.02 | $0.63 | 20.6x | +8% |
| FY2007 Q2 | Sep 30 2006 | $11.14 | $0.61 | 18.2x | -4% |
| FY2007 Q1 | Jun 30 2006 | $9.97 | $0.58 | 17.1x | -10% |
| FY2006 Q4 | Mar 31 2006 | $12.17 | $0.53 | 22.8x | +20% |
| FY2006 Q3 | Dec 31 2005 | $12.50 | $0.46 | 27.4x | +45% |
Average P/E for displayed period: 19.0x
PBH Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PBH — Frequently Asked Questions
Quick answers to the most common questions about buying PBH stock.
What is PBH's P/E ratio?
Prestige Consumer Healthcare Inc. (PBH) trailing twelve-month P/E ratio is 13.2x, based on TTM diluted EPS of $3.26. The 5-year average P/E is 15.5x and the historical range spans 10.6x to 20.0x.
Is PBH stock overvalued or undervalued?
PBH trades at 13.2x P/E, near its 5-year average of 15.5x. The 15th percentile ranking within the 10.6x–20.0x historical range places valuation within normal bounds.
Is PBH stock expensive?
PBH is fairly valued relative to its own history. The current P/E of 13.2x is near the 5-year average of 15.5x (15th percentile of historical range).
What is PBH's historical P/E range?
Over the past 5 years, PBH's P/E ratio has ranged from 10.6x to 20.0x, with a median of 15.5x and an average of 15.5x. The current P/E of 13.2x places the stock at the 15th percentile of this range. Full historical data spans 2006–2027.
How does PBH's P/E compare to the S&P 500?
PBH trades at 13.2x P/E versus the S&P 500 median of 21.8x. The 39% discount to the market suggests lower growth expectations or perceived higher risk.
How does PBH's valuation compare to Healthcare peers?
Prestige Consumer Healthcare Inc. P/E of 13.2x compares to the Healthcare sector median of 24.6x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PBH's PEG ratio?
PBH PEG ratio is 3.50, based on a P/E of 13.2x and EPS growth of -8.9%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.
What is PBH's earnings yield?
PBH earnings yield is 7.58%, the inverse of its 13.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.